T. Rowe Price Investment Management
MLTX icon

T. Rowe Price Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,557
Closed -$47K – 827
2025
Q4 		$47K Buy
+3,557
New +$42K ﹤0.01% 668
2025
Q3 		– Sell
-509
Closed -$25K – 911
2025
Q2 		$25K Buy
+509
New +$20.7K ﹤0.01% 669
2024
Q2 		– Sell
-1,095,101
Closed -$55M – 646
2024
Q1 		$55M Sell
1,095,101
-125,501
-10% -$6.81M 0.03% 377
2023
Q4 		$73.7M Buy
1,220,602
+5,879
+0.5% +$303K 0.05% 325
2023
Q3 		$69.2M Buy
1,214,723
+65,914
+6% +$3.64M 0.05% 312
2023
Q2 		$58.6M Buy
+1,148,809
New +$30.9M 0.04% 354

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Investment Management's MLTX Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 3,557 shares — an estimated $47K sold.

T. Rowe Price Investment Management first reported a position in MLTX in Q2 2023 and held it in 6 quarters. The position peaked at $73.7M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 3,557 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $47K.
  • T. Rowe Price Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 6 quarters.
  • T. Rowe Price Investment Management's MoonLake Immunotherapeutics position peaked at $73.7M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.